RxDoctor Payments Data

Allan Schwadron, MD

Cardiovascular Disease · Opelika, ALNPI 1265450878

Payments from drug & device makers

$10,893in general payments, 2019–2025

Across 368 payments — averaging $29.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Actelion Pharmaceuticals US, Inc.$1K
  • GSK$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Sanofi-aventis U.S. LLC$508
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$10,72698%
  • Education$1682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,893 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$119,346
Medicare patients
258
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$279,456
FarxigaDapagliflozin Propanediol135$120,430
VascepaIcosapent Ethyl131$97,233
JardianceEmpagliflozin107$96,677
XareltoRivaroxaban58$67,743
EntrestoSacubitril/Valsartan35$56,312
Repatha SureclickEvolocumab71$55,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$52,079
Icosapent Ethyl96$42,094
BrilintaTicagrelor22$26,868
MultaqDronedarone Hcl16$23,389
Praluent PenAlirocumab31$21,024
RybelsusSemaglutide12$18,466
Ezetimibe457$16,188
OzempicSemaglutide11$15,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$407$279,456280 claims
AstraZenecaFarxiga, Brilinta$1,087$147,297157 claims
Boehringer IngelheimJardiance$55$96,677107 claims
Johnson & JohnsonXarelto$1,166$67,74358 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,115$61,22758 claims
NovartisEntresto$290$56,31235 claims
Novo NordiskRybelsus, Ozempic$286$33,71323 claims
Sanofi-aventis U.S. LLCMultaq$508$23,38916 claims
Lilly USA, LLCMounjaro$125$13,11313 claims
Kowa Pharmaceuticals America, Inc.Livalo$22$10,65423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →